- Get involved
VP Healthcare at CEATech
Patrick Boisseau is graduated in biological engineering from the French Elite Schools Institut National Agronomique (1983) and Ecole Nationale du Génie Rural, des Eaux et des Forêts (1985). His career is fully dedicated to academic research, research and development and research management. He started his career in 1987 at CEA, a French public research organisation where he occupied several functions in biological research and later in medical technologies.
Patrick Boisseau’s current position is VP Healthcare responsible for the Strategic Planning in Life Sciences and Healthcare Technologies, at CEATech, a public non-for-profit Research & Technology Organisation, based in Grenoble, France.
He has acquired a large expertise of coordination of EU projects like the Network of Excellence Nano2Life (2004-2008), EuroNanoBio, BIBA, TARGET-PDT, and recently the EU-NCL infrastructure on nanocharacterisation. He is elected Chairman of the European Technology Platform on Nanomedicine since December 2012.
He is chairing the ESTHER Task Force designing and implementing this European Industry Driven Initiative on Emerging and Strategic Technologies for Healthcare since May 2015.
Patrick Boisseau is solicited for the numerous expertise for the European Commission and other European and national funding agencies.
Main research field: Patrick’s field of technical expertise is nanomedicine, drug delivery, medical imaging and innovative medical technologies.
Abstract Title: “Will medtech SMEs deliver the promises of P4 medicine?”
Abstract: Personalized, Predictive, Preventive, and Participatory Medicine to European patients requires Integrated healthcare solutions delivered by healthtech industries. A significant part of the innovation in the healthtech industries, covering medical devices, in vitro diagnostics, medical imaging and connected health, is delivered in Europe by about 4000 SMEs, crossings KETs into smart innovative health products. However the sustainability of these SMEs is threaten because of a) the new regulatory framework (MDR, IVDR) that will strongly impact the development and validation costs, b) the high difficulties to access to the market, c) the emergence of new business models in healthtech that breaks the old boundaries between disciplines and industries, and finally d) the impact of digitization on healthcare.
ESTHER is an Industry Driven Initiative on Emerging and Strategic Technologies for Healthcare, initiated and led by the European Commission and Medtech-Europe. The vision of ESTHER is to create an European R&D positive ecosystem to support the development and blossoming of an innovative European Health Technology Industry generating economic growth, creating jobs and providing integrated smart solutions for the benefit of patients and HealthCare systems. Its overall objective is to support the competitiveness of European Medical Technologies industries, especially SMEs, by optimising the regulatory, financial and structural ecosystem for development, manufacturing and uptake of innovative smart healthcare solutions, in a changing regulatory and healthcare environment. ESTHER provides a holistic approach of the whole innovation chain in healthtech, from early discovery to market access and reimbursement.